Claims
- 1. A method for treating or lessening the severity of reperfusion injuries, osteoporosis and/or bone metastasis comprising:
administering to a subject in need thereof a therapeutically effective amount of a compound having the structure (I): 837or pharmaceutically acceptable derivative thereof; wherein n is an integer from 0-4; R1 is hydrogen, —NH2, —NHMe, —NHAc, —OH, F, —OMe, —CN, or —NH(C═O)OEt; R2 is hydrogen, —NRARB, —ORA, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein RA and RB are each independently hydrogen or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; each occurrence of R3 is independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group —G—RC, wherein G is absent or is —CH2—, —NRD—, —O—, or (C═O), and wherein RC is hydrogen, —NRFRG, —ORF, —SRF, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein RD, RF and RG are each independently hydrogen, —NRxRy, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein RD and RC or RF and RG taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of Rx and Ry is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein Rx and Ry taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety; and a pharmaceutically acceptable carrier or diluent; and optionally further comprising administering an additional therapeutic agent.
- 2. The method of claim 1, wherein the compound has the structure:
- 3. The method of claim 1, wherein the compound has the structure:
- 4. The method of claim 1, wherein the compound has the structure:
- 5. The method of claim 1, wherein the compound has the structure:
- 6. The method of claim 1, wherein the compound has the structure:
- 7. The method of claim 1, wherein the compound has the structure:
- 8. The method of claim 1, wherein the compound has the structure:
- 9. The method of claim 1, wherein the compound has the structure:
- 10. The method of claim 1, wherein the compound has the structure:
- 11. The method of claim 1, wherein the compound has the structure:
- 12. The method of claim 1, wherein the compound has the structure:
- 13. The method of claim 1, wherein the compound has the structure:
- 14. The method of claim 1, wherein the compound has the structure:
- 15. The method of claim 1, wherein the compound has the structure:
- 16. The method of claim 1, wherein the compound has the structure:
- 17. The method of any one of claims 1-16, wherein in the compound R1 is NH2.
- 18. The method of any one of claims 1-16, wherein in the compound R1 is hydrogen.
- 19. The method of any one of claims 1-16, wherein in the compound R2 is NH2, OH, C1-C6 alkyl or C1-C6 alkenyl, said alkyl and alkenyl groups optionally substituted with halogen or hydroxyl.
- 20. The method of any one of claims 1-16, wherein in the compound R2 is C1-C2 alkyl.
- 21. The method of any one of claims 1-16, wherein in the compound R2 is methyl.
- 22. The method of any one of claims 1-16, wherein in the compound R2 is hydrogen.
- 23. The method of any one of claims 4-10, wherein in the compound one of RF or RG is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein RF and RG taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.
- 24. The method of any one of claims 4-10, wherein in the compound one of RF or RG is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein RF and RG taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.
- 25. The method of claim 24, wherein in the compound one of RF or RG is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.
- 26. The method of any one of claims 4-10, wherein in the compound one of RF or RG is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched, saturated or unsaturated aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.
- 27. The method of claim 11, wherein in the compound RF is an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.
- 28. The method of claim 12, wherein in the compound RF is hydrogen, a protecting group, or an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.
PRIORITY CLAIM
[0001] The present Application is a Continuation-In-Part and claims the benefit under 35 U.S.C. § 120 of co-pending International Application No.: PCT/US03/00366, filed Jan. 7, 2003 and published in English under PCT Article 21(2), which claims priority to U.S. Provisional Patent Application NO. 60/346,598, filed Jan. 7, 2002; the entire contents of each of these applications are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60346598 |
Jan 2002 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US03/00366 |
Jan 2003 |
US |
Child |
10753261 |
Jan 2004 |
US |